Revolution’s RMC-6291 abstract ‘reads well on efficacy,’ says Stifel
The Fly

Revolution’s RMC-6291 abstract ‘reads well on efficacy,’ says Stifel

Stifel analyst Benjamin Burnett noted that first-in-human data for Revolution Medicines’ RMC-6291 were disclosed in a late-breaking abstract for the AACR-NCI-EORTC meeting and says the abstract describes “interesting efficacy in KRAS-experienced patients.” The firm, which adds that is “positively surprised by the strong ORR signal of 57% in NSCLC,” believes the program had “taken a back seat” to the RMC-6236 program and calls the abstract “not bad for a program most had written off.” Stifel has a Buy rating on Revolution Medicines shares.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on RVMD:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App